CLDN9 Research Reagents

Claudin-9 (CLDN9) is a member of the CLDN family. As an important component of tight junctions (JT), its abnormal expression affects the function of tight junctions. earlier studies reported that CLDN9 could mediate hepatitis C virus HCV infection. Subsequent studies found that CLDN9 are crucial regulators in patients with gastric cancer. In addition, CLDN9 has been discovered to be related to glycolysis levels in endometrial and esophageal adenocarcinomas. More importantly, ample research suggested that aberrant expression of CLDN9 exerts effects on tumors such as lung cancer and liver cancer. Thus, CLDN9 is considered to be the next potent tumor marker from the CLD4 family

The transmembrane proteins of the Claudin family are key determinants of TJ permeability, but little is known about the signaling pathways that control their expression. Relevant studies have shown that CLDNs promote tumor invasion and distant metastasis by inducing EMT. The occurrence of EMT depends on the abnormal expression and activation of TYK2. Tyrosine kinase 2(tyrosine kinase 2, TYK2), as an important member of JAK protein (including four members including JAK1, JAK2, JAK3, and TYK2), can be abnormally expressed or activated in the occurrence and progression of various tumors. TYK2 is considered to be an oncogene related to tumor progression.

In one study, the authors found that the expression of CLDN9 and TYK2 in pituitary adenomas was associated with tumor invasion. In pituitary adenomas, high expression of CLDN9 may promote pituitary adenomas by inducing EMT with low expression of TYK2. Other studies have suggested that CLDN9 is up-regulated in hepatocellular carcinoma and promotes the invasion and metastasis of hepatocellular carcinoma by activating the TYK2/STAT3 signaling pathway. Other studies have shown that CLDN9 is related to glycolysis of esophageal adenocarcinoma, and high expression of CLDN9 can up-regulate the expression levels of GLUT-1, PKM2, and LDHA. In conclusion, CLDN9 is involved in the regulation of various tumors, but its specific mechanism needs to be confirmed by further research.

More Interesting read related CLDN9：Another Key Regulator for Tumors or Hearing Loss from the CLDN Family!

Popular Product

 Recombinant Human Claudin-9 (CLDN9)-VLPs (Active)  (Code: CSB-MP005511HU)

Validated Data

High Specifity Validated by Western Blot

The high specifity was validated by western blot. CSB-MP005511HU is detected by Mouse anti-6*His monoclonal antibody.

Excellent Bioactivity Validated by Functional ELISA

Immobilized Human CLDN9 at 10 μg/ml can bind Anti-CLDN6/9 recombinant antibody (CSB-RA005508MA1HU), the EC₅₀ is 24.93-35.47 ng/mL.